Dabigatran etexilate mesylate is primarily used as an oral anticoagulant to prevent and treat blood clots. It is commonly prescribed for patients with atrial fibrillation to reduce the risk of stroke and systemic embolism. Additionally, it is used for the prevention of venous thromboembolism in patients who have undergone hip or knee replacement surgery. The medication is also effective in treating deep vein thrombosis (DVT) and pulmonary embolism (PE), helping to prevent their recurrence. Its advantage lies in its direct thrombin inhibition, which offers a predictable anticoagulant effect without the need for frequent monitoring, unlike traditional anticoagulants such as warfarin.